文献速递中枢神经肿瘤放疗姑息放疗与转移瘤

放射外科与大分割立体定向放疗治疗放射抗拒性原发肿瘤(黑色素瘤和肾癌)脑转移

Radiosurgery or hypofractionated stereotactic radiotherapy for brain metastases from radioresistant primaries (melanoma and renal cancer).
PubMed 文献 · Radiat Oncol · 2018-07-28

该回顾性研究纳入2012至2016年间193个小于3 cm的黑色素瘤或肾癌脑转移灶,比较HFSRT与SRS的局部控制。中位随访7.4个月,HFSRT组与SRS组12个月LPFS分别为72%和79%,分次方案与LPFS无统计学关联(HR=1.39,95%CI 0.65-2.96,p=0.38)。作者认为HFSRT是SRS安全有效的替代治疗。

要点

  • HFSRT组与SRS组12个月LPFS分别为72%和79%,分次方案与LPFS无统计学关联。
  • 计划MRI至首次照射间隔超过14天与较差的局部控制相关,12个月LPFS从86%降至70%(p=0.009)。
  • HFSRT组放射性坏死发生率为7.1%,SRS组为9.6%,分次方案间无差异(p=0.55)。

核心结论

  • 分次方案不降低局部无进展生存。
  • 即使对于小于3 cm的放射抗拒性脑转移,采用3或6次HFSRT的1年局部控制率达72%,放射性坏死发生率为7.1%。
  • 作者认为HFSRT是SRS安全有效的替代治疗。

研究设计与样本

  • 回顾性研究,纳入2012年至2016年间193个小于3 cm的放射抗拒性原发肿瘤(黑色素瘤和肾癌)脑转移灶,接受HFSRT或SRS治疗。
  • 主要结局为6、12和18个月局部无进展生存(LPFS),次要结局为总生存(OS)和脑无进展生存(CPFS),按患者评估。
  • 统计分析包括补充性倾向性评分分析以处理非随机数据偏倚。

主要发现

  • 中位随访7.4个月,全人群6、12和18个月LPFS率分别为83%、74%和70%。
  • SRS组6、12和18个月LPFS率分别为89%、79%和73%,HFSRT组分别为80%、72%和68%。
  • 分次方案与LPFS无统计学关联(HR=1.39,95%CI 0.65-2.96,p=0.38)。
  • 计划MRI至首次照射间隔超过14天与较差的局部控制率相关,12个月LPFS从86%降至70%(p=0.009)。
  • HFSRT组放射性坏死发生率为7.1%,SRS组为9.6%,分次方案间无差异(p=0.55)。

关键数值与推荐

  • HFSRT采用3或6次分次方案。
  • 脑转移灶大小小于3 cm。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Until 50% of patients with renal cancer or melanoma, develop brain metastases during the course of their disease. Stereotactic radiotherapy has become a standard of care for patients with a limited number of brain metastases. Given the radioresistant nature of melanoma and renal cancer, optimization of the fractionation of stereotactic radiotherapy is needed. The purpose of this retrospective study was to elucidate if hypofractionated stereotactic radiotherapy (HFSRT) impacts local control of brain metastases from radioresistant tumors such as melanoma and renal cancer, in comparison with radiosurgery (SRS). METHODS: Between 2012 and 2016, 193 metastases, smaller than 3 cm, from patients suffering from radioresistant primaries (melanoma and renal cancer) were treated with HFSRT or SRS. The primary outcome was local progression free survival (LPFS) at 6, 12 and 18 months. Overall survival (OS) and cerebral progression free survival (CPFS) were secondary outcomes, and were evaluated per patient. Objective response rate and radionecrosis incidence were also reported. The statistical analysis included a supplementary propensity score analysis to deal with bias induced by non-randomized data. RESULTS: After a median follow-up of 7.4 months, LPFS rates at 6, 12 and 18 months for the whole population were 83, 74 and 70%, respectively. With respect to fractionation, LPFS rates at 6, 12 and 18 months were 89, 79 and 73% for the SRS group and 80, 72 and 68% for the HFSRT group. The fractionation schedule was not statistically associated with LPFS (HR = 1.39, CI95% [0.65-2.96], p = 0.38). Time from planning MRI to first irradiation session longer than 14 days was associated with a poorer local control rate. Over this time, LPFS at 12 months was reduced from 86 to 70% (p = 0.009). Radionecrosis occurred in 7.1% for HFSRT treated metastases to 9.6% to SRS treated metastases, without any difference according to fractionation (p = 0.55). The median OS was 9.6 months. Six, 12 and 18 months CPFS rates were 54, 24 and 17%, respectively. CONCLUSION: Fractionation does not decrease LPFS. Even for small radioresistant brain metastases (< 3 cm), HFSRT, with 3 or 6 fractions, leads to an excellent local control rate of 72% at 1 year with a rate of 7.1% of radionecrosis. HFSRT is a safe and efficient alternative treatment to SRS.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lesueur P, Lequesne J, Barraux V, et al. Radiosurgery or hypofractionated stereotactic radiotherapy for brain metastases from radioresistant primaries (melanoma and renal cancer). Radiat Oncol. 2018. PMID: 30055640. doi:10.1186/s13014-018-1083-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。